Barclays Rates Envista (NVST) buy, $32 Price Target
Barclays has reiterated its buy rating for Envista Holdings Corporation, setting a price target of $32, a 29.66% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Envista Holdings Corporation ($NVST) "buy" with a $32 price target on June 11, 2026.
Since the rating, $NVST is up 5.8% after 1 week, up 7.0% after 1 month and down 6.5% to date (from the $24.50 close on Jun 11, 2026).
NVST
Envista Holdings Corporation
Key Points
- Barclays has reiterated its buy rating for Envista Holdings Corporation with a target price of $32, reflecting confidence amid recent market activity.
- Barclays's $32 price target implies 29.66% upside from Envista Holdings Corporation's ($NVST) current $24.68 share price.
- The stock is currently priced at $24.68, below the target, which could indicate room for growth if the company performs as expected.
- Envista operates in the healthcare sector, specifically in dental products, with a market cap of $3.77 billion and a P/E ratio of 39.17.
Get $NVST trade alerts by text
We text you when insiders, Congress or big funds trade $NVST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Envista Holdings Corporation alert may contain errors. Disclosures
Barclays Maintains Buy Rating on Envista Holdings
On June 11, 2026, Barclays reiterated its buy rating for Envista Holdings Corporation (NYSE: NVST) with a price target of $32. The stock was trading at $24.68 at the time. This price target shows Barclays' belief in the company's future performance despite current market conditions.
Why Barclays Sees Potential in Envista
Barclays' latest call reflects a positive outlook for Envista, especially given its recent performance in the sector. The firm believes that the company's development and sales of dental products will drive growth, making the current share price appear undervalued compared to the target price set.
Analysts Set New Price Targets
Other analysts have varied views on Envista's stock. For instance, on October 15, 2026, Baird downgraded its rating to Neutral with a target price of $26, down from $34. Meanwhile, JP Morgan upgraded its stance to Overweight on September 3, 2026, setting a price target of $32. Meanwhile, Piper Sandler maintained its Neutral rating with a target of $26. These differing opinions reflect the mixed sentiment surrounding the company despite Barclays' optimistic outlook.
Stock Performance Context
Envista's shares are currently trading near the low end of their 52-week range, which is between $18.77 and $30.42. This could attract investors looking for potential value. The stock closed at $22.82 prior to the analyst's call, indicating that it has some catching up to do relative to the price target set by Barclays.
$NVST price target
Envista Holdings Corporation daily closes and this analyst's $32 target. Not advice.
Recent Earnings
Envista reported revenue of approximately $2.86 billion with a revenue growth rate of 7.1% in its latest earnings. The company posted an EPS of $0.60. It is set to announce its next earnings on November 4, 2026, which could further affect analyst ratings and investor sentiment.
About Envista Holdings
Envista Holdings Corporation develops and sells dental products globally, including implant systems and orthodontic products. With a focus on innovation in dental technologies, the company's performance will be closely monitored by analysts and investors alike.
Looking Ahead for Envista
As Envista prepares for its next earnings report on November 4, 2026, further changes in analyst ratings and market conditions may influence its share price. The recent 13F filings will offer insights into institutional investors' positions, but the current analyst consensus remains a key indicator of future performance.
Related Filing Alerts
Source: Barclays's rating change on $NVST (Jun 11, 2026). Written by software, not financial advice. How we make alerts